Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART versus standard budesonide/formoterol-based therapy in high-risk asthma
ACTRN12610000515099Phase 4Completed
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Jun 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide + formoterol and salbutamol in asthma (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Proportion of high beta-agonist use episodes. Started Jun 2010; status: completed.
02
Drugs
budesonide + formoterolsalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12610000515099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000515099.